Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
41.10
-2.64 (-6.04%)
At close: Feb 27, 2026, 4:00 PM EST
41.05
-0.05 (-0.12%)
After-hours: Feb 27, 2026, 7:04 PM EST
Crinetics Pharmaceuticals Revenue
In the year 2025, Crinetics Pharmaceuticals had annual revenue of $7.70M with 640.71% growth.
Revenue (ttm)
$9.23M
Revenue Growth
+344.23%
P/S Ratio
559.17
Revenue / Employee
$17,611
Employees
437
Market Cap
4.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 6.66M | 640.71% |
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
| Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
| Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
| Dec 31, 2016 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Centessa Pharmaceuticals | 15.00M |
CRNX News
- 2 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 5 weeks ago - Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire